Áß°£¿±Áٱ⼼Æ÷/¾à¿ë ½Ã±×³Î ¼¼Æ÷(MSC) ½ÃÀå : Áøº¸¿Í ÀÀ¿ë(2025³â)
Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2025
»óǰÄÚµå : 1608266
¸®¼­Ä¡»ç : BioInformant Worldwide LLC
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 380 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,197 £Ü 6,072,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,797 £Ü 6,940,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,297 £Ü 7,664,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

MSC´Â ´Ù´É¼º ¼¼Æ÷·Î, ±× ´Ù¿ëµµ¼º°ú ´Ù¾çÇÑ ¿ëµµ¸¦ ¹Ý¿µÇÏ¿© °£¿±Áٱ⼼Æ÷, ¾à¿ë½ÅÈ£¼¼Æ÷, °£¿±°£Áú¼¼Æ÷ µîÀ¸·Î ºÒ¸®¸ç, °ñ¾Æ¼¼Æ÷, ¿¬°ñ¼¼Æ÷, ±ÙÀ°¼¼Æ÷, Áö¹æ¼¼Æ÷ µî ´Ù¾çÇÑ ¼¼Æ÷ÇüÀ¸·Î ºÐÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¶Á÷ ȸº¹À» ÃËÁøÇÏ´Â ÀÎÀÚ¸¦ ºÐºñÇϰí, Ç׿°Áõ ÀÛ¿ë°ú Ç×¼¶À¯È­ ÀÛ¿ëÀ» ÅëÇØ ¹Ì¼¼È¯°æÀ» Á¶ÀýÇÏ´Â µ¶Æ¯ÇÑ ´É·ÂÀ» °¡Áö°í ÀÖÀ¸¸ç, Àç»ýÀÇ·á¿¡ ÀÖÀ¸¸ç, ÇʼöÀûÀÎ Á¸Àç°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ MSC´Â ¸é¿ªÄ§½À¼º Ư¼ºÀ¸·Î ÀÎÇØ µ¿Á¾ À̽Ŀ¡ ƯÈ÷ ÀûÇÕÇÕ´Ï´Ù.

MSC´Â Àç»ýÀÇ·á, È­Àåǰ, ¹è¾çÀ° »ý»ê µî ´Ù¾çÇÑ »ê¾÷¿¡¼­ Áß¿äÇÑ ¿ø·á·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°è¿¡¼­ 12°³ÀÇ MSC ±â¹Ý Ä¡·áÁ¦°¡ ´Ù¾çÇÑ ÀûÀÀÁõÀ¸·Î ½ÂÀεǾúÀ¸¸ç, ´ëºÎºÐ Çѱ¹, ÀϺ», EU¿¡ ÁýÁߵǾî ÀÖ½À´Ï´Ù.

ƯÈ÷ Çѱ¹¿¡¼­´Â 5°³ Á¦Ç°ÀÌ ½ÂÀεǰí ÀÖ½À´Ï´Ù. ±¸Ã¼ÀûÀ¸·Î Çѱ¹¿¡¼­´Â AnterogenÀÇ Queencell, PharmicellÀÇ Cellgram AMI, AnterogenÀÇ Cupistem, MedipostÀÇ Cartistem, CorestemÀÇ NeuroNataR µî 5°³ Á¦Ç°ÀÌ ½ÂÀεǰí ÀÖ½À´Ï´Ù. ÀϺ»¿¡¼­´Â JCRÀÇ Temcell HS¿Í Nipro CorporationÀÇ Stemirac µî 2°³ Á¦Ç°ÀÌ ½ÂÀεǰí ÀÖ½À´Ï´Ù. Àεµ¿¡¼­´Â 1°³ Á¦Ç°ÀÌ ½ÂÀεǾú½À´Ï´Ù. ÀÌ·¯ÇÑ ÁøÀü¿¡µµ ºÒ±¸ÇÏ°í ¹Ì±¹ FDAÀÇ ½ÂÀÎÀ» ¹ÞÀº MSC ±â¹Ý Ä¡·áÁ¦´Â ¾ÆÁ÷ ¾ø½À´Ï´Ù.

È­Àåǰ ½ÃÀåµµ MSC À¯·¡ Á¦Ç°, ƯÈ÷ ¿¢¼ÒÁ»À» ºü¸£°Ô äÅÃÇÏ¿© ³ëÈ­ ¹æÁö ¹× Àç»ý Ư¼ºÀ» Ȱ¿ëÇϰí ÀÖÀ¸¸ç, L'Oreal ¹× Johnson & Johnson°ú °°Àº ȸ»ç´Â ÀÌ ºÐ¾ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î ¹è¾çÀ° ±â¾÷Àº MSC¸¦ ±ÙÀ°°ú Áö¹æ ¼¼Æ÷ »ý»ê¿¡ Ȱ¿ëÇÏ¿© ¸À°ú Áú°¨À» °³¼±Çϱâ À§ÇØ MSC¸¦ Ȱ¿ëÇϰí ÀÖÀ¸¸ç, ¾÷»çÀ̵å Ǫµå(Upside Foods)¿Í ±Â¹ÌÆ®(Good Meat)ÀÇ ·¦±×·Î¿î ġŲ°ú °°Àº ȹ±âÀûÀÎ ½ÂÀÎÀº ÀÌ »ê¾÷ÀÌ ´õ¿í ¼ºÀåÇÒ ¼ö ÀÖ´Â ±æÀ» ¿­¾ú½À´Ï´Ù.

MSC¸¦ ±â¹ÝÀ¸·Î ÇÑ À¯ÀüÀÚ ÆíÁýÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, Ç×Á¾¾ç À¯ÀüÀÚ ¹× Ä¡·á ÀÎÀÚÀÇ °ú¹ßÇöÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ¶ÇÇÑ 3D ÇÁ¸°ÆÃ°ú ÀΰøÀå±â Á¦Á¶¿¡ MSC¸¦ Ȱ¿ëÇÏ´Â ¹æ¾ÈÀ» ¸ð»öÇϰí ÀÖÀ¸¸ç, ÇâÈÄ 10³â ³»¿¡ ºñ¾àÀûÀÎ ¹ßÀüÀÌ ¿¹»óµË´Ï´Ù.

Áß°£¿±Áٱ⼼Æ÷/¾à¿ë ½Ã±×³Î ¼¼Æ÷(MSC) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, MSC ÀÓ»ó½ÃÇè, °úÇÐ³í¹®, ƯÇã, ÀÚ±ÝÁ¶´Þ À̺¥Æ®, °øµ¿ ¿¬±¸ÀÇ ºñÀ²À» ¼Ò°³Çϰí ÀÖ½À´Ï´Ù. MSC ±â¹Ý Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀ» ¼Ò°³Çϰí, ½ÃÀå ±âȸ¿Í À§ÇùÀ» ½Äº°Çϰí, ÇâÈÄ ¹æÇ⼺°ú »õ·Î¿î ¿ëµµ¸¦ ¸ð»öÇÕ´Ï´Ù. ¶ÇÇÑ 125°³ÀÇ ÁÖ¿ä °æÀï»ç°¡ Á¦°øÇÏ´Â Çõ½ÅÀûÀÎ MSC Á¦Ç°, ¼­ºñ½º, ±â¼úÀ» ¼Ò°³Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ¼¼°è MSC ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå ±Ô¸ð¸¦ Áö¿ªº°, »ç¾÷ ºÐ¾ßº°·Î ºÐ·ùÇϰí, 2031³â±îÁöÀÇ ¿¹ÃøÀ» °ÔÀçÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå º¸°í¼­ °³¿ä

Á¦2Àå Áß°£¿±Áٱ⼼Æ÷(MSC) : °³¿ä

Á¦3Àå MSC ±â¹Ý ÀÓ»ó½ÃÇèÀÇ »óȲ

Á¦4Àå Áß°£¿±Áٱ⼼Æ÷(MSCS) : ƯÇã »óȲ

Á¦5Àå MSCS¿¡ °üÇÑ ÃâÆÇµÈ °úÇÐ³í¹®

Á¦6Àå MSC Á¦Á¶ Ç÷§Æû : °³¿ä

Á¦7Àå ¼¼Æ÷¡¤À¯ÀüÀÚ Ä¡·á ¼öŹÁ¦Á¶

Á¦8Àå MSCÀÇ ±â´ÉÀ» ³ôÀÌ´Â ¹ÙÀÌ¿À¿£Áö´Ï¾î¸µ ¼Ö·ç¼Ç

Á¦9Àå MSCS°¡ ´ëóÇÏ´Â ÁÖ¿ä Áúȯ

Á¦10Àå MSC ºÎ¹®¿¡¼­ÀÇ ÃÖ±Ù Çù¾÷, 2020-2024³â

Á¦11Àå ½ÃÀåÀÇ MSC ±â¹Ý Á¦Ç°

Á¦12Àå ½ÃÀå ºÐ¼®

Á¦13Àå ±â¾÷ °³¿ä

µµÇ¥ »öÀÎ

Ç¥ »öÀÎ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

EXECUTIVE SUMMARY

MSCs are multipotent cells that have been referred to as mesenchymal stem cells, medicinal signaling cells, and mesenchymal stromal cells, reflecting their versatility and diverse applications. MSCs can differentiate into a variety of cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes. Their unique ability to secrete factors that promote tissue repair and modulate their microenvironment with anti-inflammatory and anti-fibrotic effects makes them essential in regenerative medicine. Furthermore, their immuno-evasive properties make MSCs particularly suitable for allogenic transplantation.

MSCs serve as vital raw materials across numerous industries, including regenerative medicine, cosmeceuticals, and cultured meat production.

Key applications include:

Globally, 12 MSC-based therapies have been approved for various indications, with the majority concentrated in South Korea, Japan, and the EU.

Specifically, the Republic of Korea has approved five products: Queencell from Anterogen, Cellgram AMI from Pharmicell, Cupistem from Anterogen, Cartistem from Medipost, and NeuroNataR from Corestem. Japan has approved two products: Temcell HS from JCR Pharmaceuticals and Stemirac from Nipro Corporation. The EMA in Europe has approved two products: Holoclar from Chiesi Farmaceutici and Alofisel from TiGenix/Takeda. India has approved one product: Stempeucel from Stempeutics. Iran has approved one product: MesestroCell developed by Cell Tech Pharmed. Finally, Australia has approved one product: Remestemcel-L from Mesoblast.

Despite this progress, no MSC-based therapeutic have yet received U.S. FDA approval, although the FDA is actively reviewing Mesoblast's Remestemcel-L.

The cosmeceutical market is also rapidly adopting MSC-derived products, particularly exosomes, to leverage their anti-aging and regenerative properties, with companies like L'Oreal and Johnson & Johnson investing heavily in this space. Similarly, cultured meat companies are utilizing MSCs for producing muscle and fat cells, enhancing taste and texture. Groundbreaking approvals, such as lab-grown chicken by Upside Foods and Good Meat, have paved the way for further growth in this industry.

MSC-based gene editing is expanding, enabling the overexpression of antitumor genes and therapeutic factors. Researchers are also exploring the use of MSCs in 3D printing and engineered organ production, with breakthroughs anticipated in the next decade.

Importantly, companies like Cynata Therapeutics are pioneering iPSC-derived MSC production technologies, enabling large-scale therapeutic development. Today there are at least eight companies who are involved with the development of iPSC-derived MSCs therapeutics (iMSCs), including Cynata Therapeutics, Eterna Therapeutics, Implant Therapeutics, Bone Therapeutics, Brooklyn ImmunoTherapeutics, Fujifilm CDI, Citius Pharmaceuticals, and Kiji Therapeutics.

There are also over 1,670 clinical trials involving MSCs are registered on ClinicalTrials.gov. Nearly 75% (three-quarters) of these clinical studies are using MSCs for the development of regenerative medicine (RM) products. Approximately 14% of the studies are using MSCs for disease modeling. The remaining 11% of the studies are using MSCs for drug discovery and cytotoxicity testing applications.

Challenges in these trials include maintaining MSC phenotype and functionality during expansion. However, ongoing advancements suggest a promising future, with projections for at least 50 globally approved MSC-based products by 2040, averaging 3-4 new approvals annually.

Key Players in MSC Research Products

The demand for MSC-based research products has surged in recent years, with major suppliers expanding their portfolios. Companies like RoosterBio have increased the access to quality MSCs through supply chain industrialization, standardized cell bank product forms, and fit-for-purpose cGMP-compatible cells and media systems.

Other leading MSC research product suppliers include: PromoCell, Lonza, Thermo Fisher Scientific, STEMCELL Technologies, Miltenyi Biotec, Bio-Techne (R&D Systems), ScienCell Research Laboratories, and the ATCC.

Challenges and Opportunities

While MSC commercialization faces hurdles-such as scalability and regulatory approval-opportunities abound. The market for MSC-based products is poised for notable growth across the research, therapeutic, cosmetic, and food industries.

Within this rapidly changing landscape, having a thorough understanding of the competition is essential.

This global strategic report presents rates of MSC clinical trials, scientific publications, patents, funding events, and collaborations. It presents the pipeline for MSC-based therapeutics, identifies market opportunities and threats, and explores future directions and emerging applications. It reveals innovative MSC products, services, and technologies offered by 125 leading competitors. Finally, it presents detailed market size figures for the global MSC market, segmented by geography and business segment with future forecasts through 2031.

TABLE OF CONTENTS

1. REPORT OVERVIEW

2. MESENCHYMAL STEM CELLS (MSCs): AN OVERVIEW

3. MSC-BASED CLINICAL TRIAL LANDSCAPE

4. MESENCHYMAL STEM CELLS (MSCS): PATENT LANDSCAPE

5. PUBLISHED SCIENTIFIC PAPERS ON MSCS

6. MSC MANUFACTURING PLATFORMS: AN OVERVIEW

7. CELL & GENE THERAPY CONTRACT MANUFACTURING

8. BIOENGINEERING SOLUTIONS TO BOOST MSC'S FUNCTIONS

9. MAJOR DISEASES ADDRESSED BY MSCS

10. RECENT COLLABORATIONS IN MSC SECTOR, 2020-2024

11. MSC-BASED PRODUCTS IN THE MARKET

12. MARKET ANALYSIS

13. COMPANY PROFILES

INDEX OF FIGURES

INDEX OF TABLES

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â